Profiling the Structural Determinants for the Selectivity of Representative Factor-Xa and Thrombin Inhibitors Using Combined Ligand-Based and Structure-Based Approaches

The current study deciphers the combined ligand- and structure-based computational insights to profile structural determinants for the selectivity of representative diverse classes of FXa-selective and thrombin-selective as well as dual FXa-thrombin high affinity inhibitors. The thrombin-exclusive insertion 60-loop (D-pocket) was observed to be one of the most notable recognition sites for the known thrombin-selective inhibitors. Based on the topological comparison of four common active-site pockets (S1-S4) of FXa and thrombin, the greater structural disparity was observed in the S4-pocket, which was more symmetrical (U-shaped) in FXa as compared to thrombin mainly due to the presence of L99 and I174 residues in latter in place of Y99 and F174 respectively in former protease. The S2 pocket forming partial roof at the entry of 12 Å deep S1-pocket, with two extended β-sheets running antiparallel to each other by undergoing U-turn (∼180̊), has two conserved glycine residues forming H-bonds with the bound ligand for governing ligand binding affinity. The docking, scoring, and binding pose comparison of the representative high-affinity and selective inhibitors into the active sites of FXa and thrombin revealed critical residues (S214, Y99, W60D) mediating selectivity through direct- and long-range electrostatic interactions. Interestingly, most of the thrombin-selective inhibitors attained S-shaped conformation in thrombin, while FXa-selective inhibitors attained L-shaped conformations in FXa. The role of residue at 99th position of FXa and thrombin toward governing protease selectivity was further substantiated using molecular dynamics simulations on the wild-type and mutated Y99L FXa bound to thrombin-selective inhibitor 2. Furthermore, predictive CoMFA (FXa q² = 0.814; thrombin q² = 0.667) and CoMSIA (FXa q² = 0.807; thrombin q² = 0.624) models were developed and validated (FXa r²(test) = 0.823; thrombin r(2)(test) = 0.816) to feature molecular determinants of ligand binding affinity using the docking-based conformational alignments (DBCA) of 141 (88(train)+53(test)) and 39 (27(train)+11(test)) nonamidine class of potent FXa (0.004 ≤ K(i) (nM) ≤ 4700) and thrombin (0.001 ≤ K(i) (nM) ≤ 940) inhibitors, respectively. Interestingly, the ligand-based insights well corroborated with the structure-based insights in terms of the role of steric, electrostatic, and hydrophobic parameters for governing the selectivity for the two proteases. The new computational insights presented in this study are expected to be valuable for understanding and designing potent and selective antithrombotic agents.

[1]  B. Bhongade,et al.  3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis. , 2005, Bioorganic & medicinal chemistry.

[2]  D. Davey,et al.  Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors. , 2003, Bioorganic & medicinal chemistry letters.

[3]  Anshuman Dixit,et al.  An investigation of structurally diverse carbamates for acetylcholinesterase (AChE) inhibition using 3D-QSAR analysis. , 2008, Journal of molecular graphics & modelling.

[4]  G. Lip,et al.  Apixaban, an oral, direct inhibitor of activated Factor Xa. , 2008, Current opinion in investigational drugs.

[5]  R. Huber,et al.  Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of factor Xa and selectivity against thrombin , 1995, FEBS letters.

[6]  Bin Ye,et al.  Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. , 2007, Journal of medicinal chemistry.

[7]  M. Bock,et al.  Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position. , 1997, Journal of medicinal chemistry.

[8]  R. Huber,et al.  Structure of human des(1-45) factor Xa at 2.2 A resolution. , 1993, Journal of molecular biology.

[9]  Daniel L Cheney,et al.  Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity. , 2002, Bioorganic & medicinal chemistry letters.

[10]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[11]  J. Weitz,et al.  New Antithrombotic Drugs , 2009, Clinical pharmacology and therapeutics.

[12]  A. Spada,et al.  Crystal structures of human factor Xa complexed with potent inhibitors. , 2000, Journal of medicinal chemistry.

[13]  Gerhard Klebe,et al.  Comparative Molecular Similarity Index Analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries , 1999, J. Comput. Aided Mol. Des..

[14]  M. Adler,et al.  Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa. , 2007, Bioorganic & medicinal chemistry.

[15]  Gyanendra Pandey,et al.  3D QSAR Studies on Protein Tyrosine Phosphatase 1B Inhibitors: Comparison of the Quality and Predictivity among 3D QSAR Models Obtained from Different Conformer-Based Alignments , 2006, J. Chem. Inf. Model..

[16]  Hans Matter,et al.  Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa. , 2002, Journal of medicinal chemistry.

[17]  Anil K. Saxena,et al.  Consensus Superiority of the Pharmacophore-Based Alignment, Over Maximum Common Substructure (MCS): 3D-QSAR Studies on Carbamates as Acetylcholinesterase Inhibitors , 2009, J. Chem. Inf. Model..

[18]  H. Kubinyi,et al.  3D QSAR in drug design. , 2002 .

[19]  Hans Matter,et al.  Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions. , 2005, Journal of medicinal chemistry.

[20]  S. Kunitada,et al.  Molecular model of an interaction between factor Xa and DX-9065a, a novel factor Xa inhibitor: Contribution of the acetimidoylpyrrolidine moiety of the inhibitor to potency and selectivity for serine proteases , 1995 .

[21]  H. Nar,et al.  Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors. , 2001, Structure.

[22]  G Klebe,et al.  Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.

[23]  Robert Huber,et al.  X-ray Structure of Active Site-inhibited Clotting Factor Xa , 1996, The Journal of Biological Chemistry.

[24]  G Klebe,et al.  Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition. , 2001, Journal of molecular biology.

[25]  S. Haas New anticoagulants - towards the development of an "ideal" anticoagulant. , 2009, VASA. Zeitschrift fur Gefasskrankheiten.

[26]  Mika A. Kastenholz,et al.  GRID/CPCA: a new computational tool to design selective ligands. , 2000, Journal of medicinal chemistry.

[27]  Lawrence C Kuo,et al.  Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors. , 2004, Journal of medicinal chemistry.

[28]  A. Ortiz,et al.  Comparative binding energy analysis considering multiple receptors: a step toward 3D-QSAR models for multiple targets. , 2006, Journal of medicinal chemistry.

[29]  Angelo Carotti,et al.  An Integrated Approach to Ligand- and Structure-Based Drug Design: Development and Application to a Series of Serine Protease Inhibitors , 2008, J. Chem. Inf. Model..

[30]  F. Diederich,et al.  Cation-pi interactions at the active site of factor Xa: dramatic enhancement upon stepwise N-alkylation of ammonium ions. , 2009, Angewandte Chemie.

[31]  B. Xin,et al.  Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits , 2009, Journal of thrombosis and haemostasis : JTH.

[32]  D. Cheney,et al.  Factor Xa inhibitors: next-generation antithrombotic agents. , 2010, Journal of medicinal chemistry.

[33]  Maj Schuster,et al.  From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3. , 2007, Bioorganic & medicinal chemistry letters.

[34]  Sung-Hou Kim,et al.  Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. , 2000, Biochemistry.

[35]  C. Chang,et al.  Unexpected binding mode of tick anticoagulant peptide complexed to bovine factor Xa. , 1998, Journal of molecular biology.

[36]  Anil K. Saxena,et al.  Structural Basis for the β-Adrenergic Receptor Subtype Selectivity of the Representative Agonists and Antagonists , 2011, J. Chem. Inf. Model..

[37]  J. Ansell Factor Xa or thrombin: is factor Xa a better target? , 2007, Journal of thrombosis and haemostasis : JTH.

[38]  Sung-Hou Kim,et al.  Structural basis for chemical inhibition of human blood coagulation factor Xa. , 1998, Proceedings of the National Academy of Sciences of the United States of America.